Continuum Biosciences Company
Continuum is developing safe and innovative drugs that improve mitochondrial health. The company's focus is Nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease, results from fat accumulation, injury (ballooning) and inflammation in the liver. NASH can lead to liver cirrhosis or liver cancer. Scientists at Continuum are developing novel drugs as innovative treatments for NASH.
Technology:
Apps & Platforms
Industry:
Small&Large Molecules
Headquarters:
Blacksburg, Virginia, United States
Founded Date:
2020
Funding Status:
M&A
Estimated Revenue:
$10M to $50M
Register and Claim Ownership